Skip to content

Effects and Safety of Oliceridine in Anesthesia Induction:A Randomised Controlled Trial

Study of Effects and Underlying Mechanisms of Analgesic Drugs on Inflammatory Pathways and Immune Function in Patients With Endometrial Cancer

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07372209
Enrollment
120
Registered
2026-01-28
Start date
2025-10-01
Completion date
2025-12-31
Last updated
2026-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecological Laparoscopic Surgery, General Anesthetic, Intubation

Brief summary

to investigate whether oliceridine is safe and effective for induction of anesthesia by comparing henodynamic changes before and after endotracheal intubation with sufentanil

Interventions

Oliceridine is diluted to a 1mg/kg injection solution

DRUGSufentanil

sufentanil is diluted to a 5μg/ml injection solution

Sponsors

Tangshan Maternal and Child Health Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Age 18-65 years; 2. American Society of Anesthesiologists (ASA) physical status I-II; 3. Elective gynecologic laparoscopic surgery; 4. Expected operative time 60-180 minutes;

Exclusion criteria

1. Severe cardiovascular instability (e.g., acute decompensated heart failure, acute myocardial infarction, or life-threatening arrhythmia); 2. Uncontrolled hypertension; 3. Severe renal or hepatic dysfunction; 4. Severe mental disorder or psychiatric illness; 5. Known allergy or hypersensitivity to opioids; 6. History of alcohol abuse or opioid addiction; 7. Anticipated difficult airway; 8. Pregnancy or lactation;

Design outcomes

Primary

MeasureTime frame
blood pressurebaseline, at the moment of intubation, right after intubation, 1 minute、3 minutes, and 5 minutes after intubation
heart beatbaseline, at the moment of intubation, right after intubation, 1 minute、3 minutes, and 5 minutes after intubation

Secondary

MeasureTime frame
adverse reactionsfrom the administration of sufentanil or oliceridine until discharge from the post-anesthesia care unit (PACU)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026